According to filings with the U.S. Securities and Exchange Commission, Carna is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Carna
Our goal is to disrupt the trajectory of end-stage kidney disease through integrated digital health screening, monitoring of disease progression, and predictive analytics that enable decision-support opportunities. Our clinical-grade, CE-cleared devices, like Nova Pro Max Creatinine and Nova Biomedical Allegro, instantly provide crucial health metrics such as creatinine, eGFR (Estimated Glomerular Filtration Rate), and uACR (Urine Albumin to Creatinine Ratio) from just a few drops of blood, urine, and vital signs. These results are immediate and shareable in real-time with the clinical team through our state-of-the-art connectivity technology. The Carna platform, featuring the user-friendly Carna Patient App, Carna Care Team App and Carna Physician Portal, integrates effortlessly with existing healthcare systems’ EHRs. This synergy ensures a proactive, smooth and personalized healthcare journey, connecting patients and healthcare professionals like never before.

To learn more about Carna, visit http://www.carna.health
Carna Linkedin Page: https://www.linkedin.com/company/carna-health/

Contact:
Salvatore Viscomi, Chief Executive Officer
617-966-1055
https://www.linkedin.com/in/salvatore-viscomi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.